Bausch and Lomb does not currently have any plans to bring Zirgan to Canada. (newods.ca)
ZIRGAN4
ZIRGAN contains 0.15% of ganciclovir in a sterile preserved topical ophthalmic gel. (nih.gov)
ZIRGAN (ganciclovir ophthalmic gel) 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). (nih.gov)
ZIRGAN (ganciclovir ophthalmic gel) 0.15% contains a sterile, topical antiviral for ophthalmic use. (mdtodate.com)
ZIRGAN contains the active ingredient, ganciclovir, which is a guanosine derivative that, upon phosphorylation, inhibits DNA replication by herpes simplex viruses (HSV). (mdtodate.com)
Lomb Incorporated1
To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (nih.gov)
Systemic2
It is not known whether topical ophthalmic ganciclovir administration could result in sufficient systemic absorption to produce detectable quantities in breast milk. (nih.gov)
[ 27 ] Therefore, the implant was usually used in combination with oral ganciclovir for systemic effects. (medscape.com)
Topical1
There is clinical evidence that topical ganciclovir is effective against at least Adenovirus serotype 8, thus compelling many clinicians to prescribe this agent off-label for compelling cases of epidemic keratoconjunctivitis (EKC), particularly when corneal lesions are noted. (medscape.com)
Oral2
[ 51 ] Some strains of CMV have shown resistance to oral ganciclovir therapy. (medscape.com)
Ganciclovir implant is efficacious when the resistance to oral ganciclovir is identified genotypically, such as in the cases of UL97 and UL54 gene mutations. (medscape.com)
Shown1
Ganciclovir has been shown to be embryotoxic in rabbits and mice following intravenous administration and teratogenic in rabbits. (nih.gov)